Toll Free: 1-888-928-9744

Blepharitis - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Blepharitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Blepharitis - Pipeline Review, H2 2015', provides an overview of the Blepharitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Blepharitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Blepharitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Blepharitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Blepharitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Blepharitis Overview 6 Therapeutics Development 7 Pipeline Products for Blepharitis - Overview 7 Pipeline Products for Blepharitis - Comparative Analysis 8 Blepharitis - Therapeutics under Development by Companies 9 Blepharitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Blepharitis - Products under Development by Companies 13 Blepharitis - Companies Involved in Therapeutics Development 14 Allergan Plc 14 Foamix Pharmaceuticals Ltd. 15 InSite Vision Incorporated 16 Kala Pharmaceuticals, Inc. 17 NicOx S.A. 18 Blepharitis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 27 AGN-195263 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 dexamethasone acetate - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 fluticasone propionate - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ISV-405 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 loteprednol etabonate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 minocycline Gel - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Blepharitis - Recent Pipeline Updates 33 Blepharitis - Dormant Projects 38 Blepharitis - Product Development Milestones 39 Featured News & Press Releases 39 Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults 39 Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition 39 Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Number of Products under Development for Blepharitis, H2 2015 7 Number of Products under Development for Blepharitis - Comparative Analysis, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Comparative Analysis by Late Stage Development, H2 2015 10 Comparative Analysis by Clinical Stage Development, H2 2015 11 Comparative Analysis by Early Stage Development, H2 2015 12 Products under Development by Companies, H2 2015 13 Blepharitis - Pipeline by Allergan Plc, H2 2015 14 Blepharitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 15 Blepharitis - Pipeline by InSite Vision Incorporated, H2 2015 16 Blepharitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 17 Blepharitis - Pipeline by NicOx S.A., H2 2015 18 Assessment by Monotherapy Products, H2 2015 19 Number of Products by Stage and Target, H2 2015 21 Number of Products by Stage and Mechanism of Action, H2 2015 23 Number of Products by Stage and Route of Administration, H2 2015 25 Number of Products by Stage and Molecule Type, H2 2015 26 Blepharitis Therapeutics - Recent Pipeline Updates, H2 2015 33 Blepharitis - Dormant Projects, H2 2015 38



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify